Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Ori Toker1, Philip J Hashkes21Department of Pediatrics, Shaare Zedek Medical Center, affiliated with the Hadassah-Hebrew University Medical School, Jerusalem, Israel; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel, Cleveland Clinic Lerner Medical School, Case Western Re...
Guardado en:
Autores principales: | Ori Toker, Philip J Hashkes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe1ae3d55eaf4938abed63abd177aab2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Justin Gillespie, et al.
Publicado: (2010) -
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Leigh D Church, et al.
Publicado: (2008) -
Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Pierre Quartier
Publicado: (2011) -
Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin- associated periodic syndromes
por: Bachove I, et al.
Publicado: (2014) -
Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
por: Kawai M, et al.
Publicado: (2013)